Core Viewpoint - The upcoming earnings report for Conmed is anticipated to show a year-over-year increase in earnings and revenues, with the stock's movement largely dependent on the actual results compared to expectations [13]. Earnings Expectations - Conmed is expected to report quarterly earnings of $0.92 per share, reflecting a year-over-year increase of +10.8% [2]. - Revenues are projected to be $334.56 million, which is a 5.3% increase from the same quarter last year [3]. Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their views [4]. - The Zacks Earnings ESP model suggests that the Most Accurate Estimate is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [9]. Historical Performance - In the last reported quarter, Conmed was expected to post earnings of $0.74 per share but exceeded expectations with earnings of $0.79, resulting in a surprise of +6.76% [11]. - Over the past four quarters, Conmed has beaten consensus EPS estimates three times [19]. Current Stock Rating - Conmed currently holds a Zacks Rank of 4, indicating a "Sell" rating, which complicates the prediction of an earnings beat [10][17].

CONMED Corporation (CNMD) delivered adjusted earnings per share (EPS) of $0.79 in first-quarter 2024, which beat the Zacks Consensus Estimate of $0.74 by 6.8%. The bottom line improved 19.7% from the year-ago quarter’s level.GAAP EPS for the quarter was 63 cents compared with 6 cents per share in the year-ago period.The company’s shares have lost 25.8% in the past six months against the industry’s rise of 10.0%. The broader S&P 500 Index has gained 23% in the same time frame.Image Source: Zacks Investment R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Common Stock, $0.01 par value CNMD NYSE Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Smaller reporting company ☐ Emerging growth company ☐ The number of ...

Investor Presentation Q1 2024 Earnings Call This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forwardlooking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-lo ...

Call End: CONMED Corporation (NYSE:CNMD) Q1 2024 Earnings Conference Call April 24, 2024, 16:30 PM ET Company Participants Curt Hartman - Chair, President and Chief Executive Officer Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Matt O'Brien - Piper Sandler Young Li - Jefferies Vik Chopra - Wells Fargo Kristen Stewart - CL King Rick Wise - Stifel Robbie Marcus - J.P. Morgan Travis Steed - BofA Securities Mike Matson - Needham Operator Thank you for standing ...

For the quarter ended March 2024, Conmed (CNMD) reported revenue of $312.27 million, up 5.7% over the same period last year. EPS came in at $0.79, compared to $0.66 in the year-ago quarter.The reported revenue represents a surprise of +1.70% over the Zacks Consensus Estimate of $307.06 million. With the consensus EPS estimate being $0.74, the EPS surprise was +6.76%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...

Conmed (CNMD) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.76%. A quarter ago, it was expected that this medical technology company would post earnings of $1.11 per share when it actually produced earnings of $1.06, delivering a surprise of -4.50%.Over the last four quarters, the ...

Financial Performance - CONMED Corporation reported net sales of $312.3 million for Q1 2024, a 5.7% increase from $295.5 million in Q1 2023[6] - Gross profit for the quarter was $171.965 million, representing 55.1% of sales, compared to 52.6% in the same quarter last year[6] - Income from operations increased to $35.013 million, or 11.2% of sales, up from $12.699 million, or 4.3% of sales, in Q1 2023[6] - Net income for Q1 2024 was $19.709 million, significantly higher than $1.819 million in Q1 2023[6] - Basic EPS for the quarter was $0.64, compared to $0.06 in the prior year[6] - Diluted net earnings per share (GAAP) were $0.63, compared to $0.06 in Q1 2023[22] - Adjusted diluted net earnings per share increased by 19.7% to $0.79 compared to Q1 2023[22] - EBITDA for Q1 2024 was $53.051 million, with an EBITDA margin of 17.0%, up from 10.4% in Q1 2023[14] - Adjusted EBITDA for Q1 2024 was $56.301 million, with an adjusted EBITDA margin of 18.0%, compared to 17.3% in Q1 2023[14] Sales Performance - Domestic sales grew by 7.2% to $176.4 million, while international sales increased by 3.8% to $135.9 million[8] - The orthopedic surgery segment reported a 2.8% increase in sales, while general surgery sales rose by 8.0%[8] - Sales for Q1 2024 were $312.3 million, representing a 5.7% increase year-over-year and a 5.9% increase in constant currency[22] - Domestic revenue increased by 7.2% year-over-year, while international revenue increased by 3.8% as reported and 4.2% in constant currency[22] Future Guidance - The company expects full-year adjusted diluted EPS to be in the range of $4.25 to $4.35, down from the previous range of $4.30 to $4.40 due to foreign currency headwinds[1] - The company expects full-year reported revenue to be between $1.330 billion and $1.355 billion, down from previous guidance of $1.340 billion to $1.365 billion due to currency headwinds[23] Operational Adjustments - The company incurred severance costs and wrote off inventory related to the cancellation of a planned new product line in 2024[12] - The company recorded an accrual adjustment related to the termination of a distributor agreement in 2024[12] - The company continues to utilize non-GAAP financial measures to provide a clearer understanding of its operational performance[17] Growth Outlook - The company is well-positioned for continued growth with a diverse portfolio across its markets[1] - Research and development expenses increased to $13.594 million from $12.539 million year-over-year[6]

CONMED Corporation (CNMD) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid fourth-quarter 2023 performance and a potential General Surgery, is expected to contribute further. However, headwinds from supply-chain constraints and data security threats persist.This currently Zacks Rank #3 (Hold) company’s shares have lost 15.2% in the past year against the industry’s 3.2% growth. The S&P 500 Index has increased 24.8% in the same time frame ...

The changes in the net carrying amount of goodwill for the years ended December 31, are as follows: Amortization expense related to intangible assets which are subject to amortization totaled $35.2 million, $33.7 million and $33.3 million for the years ending December 31, 2023, 2022 and 2021, respectively, and is included as a reduction of revenue (for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense (for all other intangible asset ...